Literature DB >> 18082409

Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure.

Kenji Murano1, Toshio Yamanaka, Ayako Toda, Hidenori Ohki, Shinya Okuda, Kohji Kawabata, Kazuo Hatano, Shinobu Takeda, Hisashi Akamatsu, Kenji Itoh, Keiji Misumi, Satoshi Inoue, Tatsuya Takagi.   

Abstract

AmpC beta-lactamase is one of the leading causes of Pseudomonas aeruginosa (P. aeruginosa) resistance to cephalosporins. FR259647 is a cephalosporin having a novel pyrazolium substituent at the 3-position and exhibits excellent activity (MIC=1 microg/mL) against the AmpC beta-lactamase overproducing P. aeruginosa FP1380 strain in comparison with the third-generation cephalosporins FK518 [Abstracts of Papers, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-24, 1990, Abs. 454; Abstracts of Papers, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-24, 1990, Abs. 455; Abstracts of Papers, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-24, 1990, Abs. 456; Abstracts of Papers, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA, October 21-24, 1990, Abs. 457] (MIC=16 microg/mL) and ceftazidime (CAZ) (MIC=128 microg/mL). The stability of FR259647 and FK518 to AmpC beta-lactamase was evaluated using MIC assays against both the P. aeruginosa PAO1 strain and a PAO1 mutant strain overproducing AmpC beta-lactamase as a differential assay, which indicates that the main difference derives from their stability to AmpC beta-lactamase. A structural analysis using computer simulations indicated that the difference in stability may be due to steric hindrance of the 3-position substituents causing differential affinity. This steric hindrance may disturb entry of the cephalosporins into the binding pocket. We predicted the possibility of inhibition of entry as a potential means of enhancing stability by conformational analysis. In order to validate this speculation, novel FR259647 derivatives 4-9 were designed, calculated, synthesized, and evaluated. As a result, we demonstrated that their probability of entry correlated with the MIC ratio of the mutant strain to the parent strain and supports the validity of our model.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18082409     DOI: 10.1016/j.bmc.2007.11.074

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

1.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

Review 2.  Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Authors:  George G Zhanel; Phillip Chung; Heather Adam; Sheryl Zelenitsky; Andrew Denisuik; Frank Schweizer; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Andrew Walkty; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

Review 3.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors:  Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-04-26

Review 4.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

Review 5.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

Review 6.  Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia.

Authors:  Nathaniel J Rhodes; Caroline E Cruce; J Nicholas O'Donnell; Richard G Wunderink; Alan R Hauser
Journal:  Curr Infect Dis Rep       Date:  2018-03-06       Impact factor: 3.725

7.  Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam.

Authors:  Cole L Slater; Judith Winogrodzki; Pablo A Fraile-Ribot; Antonio Oliver; Mazdak Khajehpour; Brian L Mark
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 8.  Antibacterial pyrazoles: tackling resistant bacteria.

Authors:  Mohammad A Alam
Journal:  Future Med Chem       Date:  2022-01-20       Impact factor: 3.808

Review 9.  Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data.

Authors:  Silvia Garazzino; Elena Altieri; Erika Silvestro; Giulia Pruccoli; Carlo Scolfaro; Elisabetta Bignamini
Journal:  Front Pediatr       Date:  2020-05-05       Impact factor: 3.418

10.  Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency.

Authors:  Katie Stokem; Jonathan B Zuckerman; David P Nicolau; Minkey Wungwattana; Edmund H Sears
Journal:  Respir Med Case Rep       Date:  2017-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.